Qingketan^® Tedizolid Phosphate for Injection is a second-generation oxazolidinone antibiotic, used to treat acute bacterial skin and soft tissue infections (ABSSSI) caused by the following Gram-positive bacteria: Staphylococcus aureus (including Methicillin-resistant Staphylococcus aureus [MRSA] and Methicillin-sensitive Staphylococcus aureus [MSSA] isolates), Streptococcus pyogenes, Enterococcus faecalis, Streptococcus anginosus group (including Streptococcus pyogenes, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecium.

Qingketan^® Tedizolid Phosphate for Injection was launched in April 2023. It has strong antibacterial activity, excellent tissue penetration, clear clinical efficacy, low risk of resistance, and minimal drug interactions. It is currently considered an ideal treatment for Gram-positive bacterial infections.